Clinical commissioning policy statement: Use of Adalimumab for Osteomyelitis

Adalimumab is not recommended to be available as a treatment option through routine commissioning for refractory chronic non-bacterial osteomyelitis/ osteitis (all ages) due to weak evidence base.

NHS England